Pharmaceutical

EMA and FDA green-light MoonLake to advance IL-17 inhibitor

The Phase III VELA programme will compare the IL-17 inhibitor sonelokimab to a placebo, enrolling 800 patients over 52 weeks.

Feb 28, 2024 - 18:00
EMA and FDA green-light MoonLake to advance IL-17 inhibitor
The Phase III VELA programme will compare the IL-17 inhibitor sonelokimab to a placebo, enrolling 800 patients over 52 weeks.
Read the original article

Tags:

Previous Article

Beyond approval: Patients pursue alternate paths to get rare disease treatments

Next Article

AbbVie licenses OSE’s chronic inflammation therapy for $48m upfront

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: FDA chief scientist to replace Woodcock

STAT+: FDA chief scientist to replace Woodcock

Nov 29, 2023

STAT+: Novartis is scolded by U.K. trade group for the third time this year over Entresto marketing

STAT+: Novartis is scolded by U.K. trade group for the ...

Jul 18, 2023

Signal: Novo Nordisk market cap higher than Danish GDP due to obesity drugs

Signal: Novo Nordisk market cap higher than Danish GDP ...

Sep 1, 2023